Profiling human leukocyte antigens in Vogt-Koyanagi-Harada syndrome.
Human leukocyte antigen typing was performed in 32 consecutive Chinese patients with Vogt-Koyanagi-Harada syndrome and 52 unrelated healthy Chinese individuals. Results indicated that HLA-DR4 was identified in 24 of the 32 patients with Vogt-Koyanagi-Harada syndrome (75.0%), but only in 12 (23.1%) of the 52 control subjects (P = .0003; relative risk, 10.0). Human leukocyte antigen-DQw7, also correlated with the disease, was identified in 19 (59.4%) patients, and in 19 control subjects (36.5%; P = .0230). The two-haplotype association detection demonstrated that HLA-DR4 and HLA-DQw7 were related through linkage disequilibrium, suggesting that the disease was primarily associated with only one of the antigens. The comparison between HLA-DR4-positive and HLA-DR4-negative patients with Vogt-Koyanagi-Harada syndrome in regard to clinical manifestations has shown that the HLA-DR4-positive group had a lower visual acuity at the first visit than did the HLA-DR4-negative group. However, both groups responded well to corticosteroid treatment. No other significant correlations between HLA-DR4 positivity and ocular features, including complications or systemic features, were found. Therefore, we concluded that the presence of HLA-DR4 may represent susceptibility to Vogt-Koyanagi-Harada syndrome, but may not represent specific tissue involvement or determine the prognosis. A decreased frequency of HLA-DQw1 in the patient group was also noticed. Further studies showed a higher percentage of HLA-DQw1 in HLA-DR4-positive control subjects than in the HLA-DR4-positive patients (P = .0308), which indicated that HLA-DQw1 was negatively associated with the disease. This protective effect from HLA-DQw1 was also studied.
Zhang
X Y
XY
Department of Ophthalmology, Peking Union Medical College Hospital, Chinese Academy of Medical Science, Beijing.
Wang
X M
XM
Hu
T S
TS
D000293:Adolescent; D000328:Adult; D004198:Disease Susceptibility; D005260:Female; D006680:HLA Antigens / Q000097:blood*; D015234:HLA-A Antigens / Q000097:blood; D015235:HLA-B Antigens / Q000097:blood; D006683:HLA-DQ Antigens / Q000097:blood; D006684:HLA-DR Antigens / Q000097:blood; D006650:Histocompatibility Testing; D006801:Humans; D015810:Linkage Disequilibrium; D008297:Male; D008875:Middle Aged; D012307:Risk Factors; D014607:Uveomeningoencephalitic Syndrome / Q000276:immunology*; D014792:Visual Acuity
D006680:HLA Antigens; D015234:HLA-A Antigens; D015235:HLA-B Antigens; D006683:HLA-DQ Antigens; D006684:HLA-DR Antigens